Skip to main content
. 2015 Oct;5(5):364–373. doi: 10.3978/j.issn.2223-3652.2015.06.03

Table 1. Main clinical features and prevalence of diabetes mellitus (DM) in recent randomized AF trials with novel non-vitamin K antagonist oral anticoagulants.

Study RE-LY ROCKET-AF ARISTOTLE ENGAGE-AF
Drug Dabigatran Rivaroxaban Apixaban Edoxaban
Age >75 years 40% 43.7% 31.2% 40.5%
CHADS2 mean 2.2 3.48 2.1 2.8
Previous TIA/stroke 20.3% 54.9% 19.2% 28.1%
Hypertension 78.9% 90.3% 87.3% 93.7%
Diabetes 23.3% 39.9% 25% 36.4%
CHF 31.8% 62.6% 35.5% 58.2%

AF, atrial fibrillation; CHF, chronic heart failure; TIA, transient ischaemic attack; CHADS2, cardiac failure, hypertension, age, diabetes, stroke (doubled).